^
Association details:
| Biomarker: | MYCN amplification + ALK rearrangement |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Excerpt:
...brigatinib as a single agent in BalbC/NUDE mice injected with human neuroblastoma CLB-BAR cells, (ALK Δ4-11 and MYCN amplified, ALK addicted)...tumor volume showed that brigatinib considerably inhibits proliferation of tumor growth in vivo (p=0.0004)...tumor weight was significantly reduced in the brigatinib treated group as compared with controls (p=0.01)...
DOI:
10.18632/oncotarget.8508
